Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 119 articles: HTML format

Single Articles

April 2024
1. YOKOTA E, Iwai M, Yukawa T, Naomoto Y, et al
   Patient-derived tumoroid models of pulmonary large-cell neuroendocrine carcinoma: a promising tool for personalized medicine and developing novel therapeutic strategies.
   Cancer Lett. 2024;588:216816.
   PubMed     Abstract available
   
   
   
2. MOON JW, Hong BJ, Kim SK, Park MS, et al
   Systematic identification of a synthetic lethal interaction in brain-metastatic lung adenocarcinoma.
   Cancer Lett. 2024;588:216781.
   PubMed     Abstract available
   
   
   
3. MORIMOTO K, Yamada T, Hirai S, Katayama Y, et al
   AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
   Cancer Lett. 2024;587:216692.
   PubMed     Abstract available
   
   
   
4. GAO GB, Chen L, Pan JF, Lei T, et al
   LncRNA RGMB-AS1 inhibits HMOX1 ubiquitination and NAA10 activation to induce ferroptosis in non-small cell lung cancer.
   Cancer Lett. 2024 Apr 2:216826. doi: 10.1016/j.canlet.2024.216826.
   PubMed     Abstract available
   
   
   
5. HAO Z, Xin Z, Chen Y, Shao Z, et al
   JAML promotes the antitumor role of tumor-resident CD8(+) T cells by facilitating their innate-like function in human lung cancer.
   Cancer Lett. 2024 Apr 1:216839. doi: 10.1016/j.canlet.2024.216839.
   PubMed     Abstract available
   
   
   March 2024
6. ZHANG E, Sun Q, Zhang C, Ma H, et al
   Comprehensive functional interrogation of susceptibility loci in GWASs identified KIAA0391 as a novel oncogenic driver via regulating pyroptosis in NSCLC.
   Cancer Lett. 2024;585:216646.
   PubMed     Abstract available
   
   
   
7. JABBARZADEH KABOLI P, Chen HF, Babaeizad A, Roustai Geraylow K, et al
   Unlocking c-MET: A comprehensive journey into targeted therapies for breast cancer.
   Cancer Lett. 2024 Mar 8:216780. doi: 10.1016/j.canlet.2024.216780.
   PubMed     Abstract available
   
   
   
8. MADORSKY ROWDO FP, Xiao G, Khramtsova GF, Nguyen J, et al
   Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
   Cancer Lett. 2024;584:216608.
   PubMed     Abstract available
   
   
   February 2024
9. HAN R, Lin C, Lu C, Wang Y, et al
   Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
   Cancer Lett. 2024;588:216762.
   PubMed     Abstract available
   
   
   
10. LIU X, Zheng W, Zhang L, Cao Z, et al
    Arginine methylation-dependent cGAS stability promotes non-small cell lung cancer cell proliferation.
    Cancer Lett. 2024 Feb 6:216707. doi: 10.1016/j.canlet.2024.216707.
    PubMed     Abstract available
    
    
    
11. LU X, Yu R, Li Z, Yang M, et al
    JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers.
    Cancer Lett. 2024;582:216517.
    PubMed     Abstract available
    
    
    
12. LIN S, He C, Song L, Sun L, et al
    Exosomal lncCRLA is predictive for the evolvement and development of lung adenocarcinoma.
    Cancer Lett. 2024;582:216588.
    PubMed     Abstract available
    
    
    
13. BISWAS U, Roy R, Ghosh S, Chakrabarti G, et al
    The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics.
    Cancer Lett. 2024 Feb 1:216662. doi: 10.1016/j.canlet.2024.216662.
    PubMed     Abstract available
    
    
    January 2024
14. SUN J, Dong M, Xiang X, Zhang S, et al
    Notch signaling and targeted therapy in non-small cell lung cancer.
    Cancer Lett. 2024 Jan 30:216647. doi: 10.1016/j.canlet.2024.216647.
    PubMed     Abstract available
    
    
    
15. SUI Q, Hu Z, Liang J, Lu T, et al
    Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma.
    Cancer Lett. 2024;581:216497.
    PubMed     Abstract available
    
    
    
16. ZHANG H, Li S, Zhou R, Dong T, et al
    SRCAP complex promotes lung cancer progression by reprograming the oncogenic transcription of Hippo-YAP/TAZ signaling pathway.
    Cancer Lett. 2024;585:216667.
    PubMed     Abstract available
    
    
    
17. ZHOU X, Jia Y, Mao C, Liu S, et al
    Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy.
    Cancer Lett. 2024;580:216481.
    PubMed     Abstract available
    
    
    December 2023
18. YANG Y, Wang J, Wang J, Zhao X, et al
    Unrevealing the therapeutic benefits of radiotherapy and consolidation immunotherapy using ctDNA-defined tumor clonality in unresectable locally advanced non-small cell lung cancer.
    Cancer Lett. 2023 Dec 13:216569. doi: 10.1016/j.canlet.2023.216569.
    PubMed     Abstract available
    
    
    
19. MENG Y, Lin W, Wang N, Wei X, et al
    USP7-mediated ERbeta stabilization mitigates ROS accumulation and promotes osimertinib resistance by suppressing PRDX3 SUMOylation in non-small cell lung carcinoma.
    Cancer Lett. 2023 Dec 12:216587. doi: 10.1016/j.canlet.2023.216587.
    PubMed     Abstract available
    
    
    
20. XIE Y, Zhang L, Wang L, Chen B, et al
    EphB1 promotes the differentiation and maturation of dendritic cells in non-small cell lung cancer.
    Cancer Lett. 2023;582:216567.
    PubMed     Abstract available
    
    
    
21. YUAN Y, Li Y, Wu X, Bo J, et al
    POH1 induces Smad3 deubiquitination and promotes lung cancer metastasis.
    Cancer Lett. 2023 Dec 5:216526. doi: 10.1016/j.canlet.2023.216526.
    PubMed     Abstract available
    
    
    
22. KONG R, Wei W, Man Q, Chen L, et al
    Hypoxia-induced circ-CDYL-EEF1A2 transcriptional complex drives lung metastasis of cancer stem cells from hepatocellular carcinoma.
    Cancer Lett. 2023;578:216442.
    PubMed     Abstract available
    
    
    November 2023
23. ZHOU Y, Guo Y, Ran M, Shan W, et al
    Combined inhibition of pyruvate dehydrogenase kinase 1 and lactate dehydrogenase a induces metabolic and signaling reprogramming and enhances lung adenocarcinoma cell killing.
    Cancer Lett. 2023;577:216425.
    PubMed     Abstract available
    
    
    
24. NAMKAEW J, Zhang J, Yamakawa N, Hamada Y, et al
    Repositioning of mifepristone as an integrated stress response activator to potentiate cisplatin efficacy in non-small cell lung cancer.
    Cancer Lett. 2023 Nov 28:216509. doi: 10.1016/j.canlet.2023.216509.
    PubMed     Abstract available
    
    
    
25. CAI S, Zhang B, Huang C, Deng Y, et al
    CTRP6 protects against ferroptosis to drive lung cancer progression and metastasis by destabilizing SOCS2 and augmenting the xCT/GPX4 pathway.
    Cancer Lett. 2023;579:216465.
    PubMed     Abstract available
    
    
    
26. LI B, Chen Q, Feng Y, Wei T, et al
    Glucose restriction induces AMPK-SIRT1-mediated circadian clock gene Per expression and delays NSCLC progression.
    Cancer Lett. 2023;576:216424.
    PubMed     Abstract available
    
    
    October 2023
27. HUA WJ, Yeh H, Lin ZH, Tseng AJ, et al
    Ganoderma microsporum immunomodulatory protein as an extracellular epidermal growth factor receptor (EGFR) degrader for suppressing EGFR-positive lung cancer cells.
    Cancer Lett. 2023;578:216458.
    PubMed     Abstract available
    
    
    
28. ZHANG Q, Zheng L, Bai Y, Su C, et al
    ITPR1-AS1 promotes small cell lung cancer metastasis by facilitating P21(HRAS) splicing and stabilizing DDX3X to activate the cRaf-MEK-ERK cascade.
    Cancer Lett. 2023 Oct 9:216426. doi: 10.1016/j.canlet.2023.216426.
    PubMed     Abstract available
    
    
    September 2023
29. LIU X, Li R, Chen X, Yao J, et al
    SYT7 is a key player in increasing exosome secretion and promoting angiogenesis in non-small-cell lung cancer.
    Cancer Lett. 2023 Sep 27:216400. doi: 10.1016/j.canlet.2023.216400.
    PubMed     Abstract available
    
    
    August 2023
30. LI X, Ke Y, Hernandez AL, Yu J, et al
    Inducible nitric oxide synthase (iNOS)-activated Cxcr2 signaling in myeloid cells promotes TGFbeta-dependent squamous cell carcinoma lung metastasis.
    Cancer Lett. 2023;570:216330.
    PubMed     Abstract available
    
    
    
31. LI C, Shao J, Li P, Feng J, et al
    Circulating tumor DNA as liquid biopsy in lung cancer: Biological characteristics and clinical integration.
    Cancer Lett. 2023 Aug 25:216365. doi: 10.1016/j.canlet.2023.216365.
    PubMed     Abstract available
    
    
    
32. WANG Y, Zhang L, Tan J, Zhang Z, et al
    Longitudinal detection of subcategorized CD44v6(+) CTCs and circulating tumor endothelial cells (CTECs) enables novel clinical stratification and improves prognostic prediction of small cell lung cancer: A prospective, multi-center study.
    Cancer Lett. 2023 Aug 6:216337. doi: 10.1016/j.canlet.2023.216337.
    PubMed     Abstract available
    
    
    July 2023
33. LIU ZY, Lin XT, Zhang YJ, Gu YP, et al
    FBXW10-S6K1 promotes ANXA2 polyubiquitination and KRAS activation to drive hepatocellular carcinoma development in males.
    Cancer Lett. 2023;566:216257.
    PubMed     Abstract available
    
    
    
34. XU Y, Zhang X, Zhang R, Sun Y, et al
    AFP deletion leads to anti-tumorigenic but pro-metastatic roles in liver cancers with concomitant CTNNB1 mutations.
    Cancer Lett. 2023;566:216240.
    PubMed     Abstract available
    
    
    
35. LE HT, Nguyen HT, Min HY, Hyun SY, et al
    Corrigendum to "Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells" [Cancer Lett. 412 (2018) 297-307].
    Cancer Lett. 2023 Jul 7:216289. doi: 10.1016/j.canlet.2023.216289.
    PubMed    
    
    
    
36. CABAN M, Koblmueller B, Groza D, Schueffl HH, et al
    A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
    Cancer Lett. 2023;565:216237.
    PubMed     Abstract available
    
    
    
37. FENG B, Pan B, Huang J, Du Y, et al
    PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes.
    Cancer Lett. 2023;565:216224.
    PubMed     Abstract available
    
    
    
38. LIU Z, Yan W, Liu S, Liu Z, et al
    Regulatory network and targeted interventions for CCDC family in tumor pathogenesis.
    Cancer Lett. 2023;565:216225.
    PubMed     Abstract available
    
    
    May 2023
39. KANG K, Wu Y, Yao Z, Lu Y, et al
    Tackling the current dilemma of immunotherapy in extensive-stage small cell lung cancer: A promising strategy of combining with radiotherapy.
    Cancer Lett. 2023;565:216239.
    PubMed     Abstract available
    
    
    
40. LU J, Li J, Lin Z, Li H, et al
    Reprogramming of TAMs via the STAT3/CD47-SIRPalpha axis promotes acquired resistance to EGFR-TKIs in lung cancer.
    Cancer Lett. 2023;564:216205.
    PubMed     Abstract available
    
    
    
41. XU W, Patel N, Deng Y, Ding S, et al
    Extracellular vesicle-derived LINC00482 induces microglial M2 polarization to facilitate brain metastasis of NSCLC.
    Cancer Lett. 2023;561:216146.
    PubMed     Abstract available
    
    
    April 2023
42. ZHAN D, Zheng N, Zhao B, Cheng F, et al
    Expanding individualized therapeutic options via genoproteomics.
    Cancer Lett. 2023;560:216123.
    PubMed     Abstract available
    
    
    March 2023
43. XIA Y, Jin R, Li M, Lan F, et al
    Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
    Cancer Lett. 2023 Mar 20:216140. doi: 10.1016/j.canlet.2023.216140.
    PubMed     Abstract available
    
    
    
44. KLECZKO EK, Le AT, Hinz TK, Nguyen TT, et al
    Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response.
    Cancer Lett. 2023;556:216062.
    PubMed     Abstract available
    
    
    February 2023
45. YANG J, Hou C, Wang H, Perez EA, et al
    Miz1 promotes KRAS-driven lung tumorigenesis by repressing the protocadherin Pcdh10.
    Cancer Lett. 2023;555:216025.
    PubMed     Abstract available
    
    
    November 2022
46. TANG B, Wang Y, Xu W, Zhu J, et al
    Macrophage-specific xCT deficiency drives immune activation and boosts responses to immune checkpoint blockade in lung cancer.
    Cancer Lett. 2022 Nov 28:216021. doi: 10.1016/j.canlet.2022.216021.
    PubMed     Abstract available
    
    
    
47. TIAN Y, Xu L, Li X, Li H, et al
    SMARCA4: Current status and future perspectives in non-small-cell lung cancer.
    Cancer Lett. 2022 Nov 27:216022. doi: 10.1016/j.canlet.2022.216022.
    PubMed     Abstract available
    
    
    October 2022
48. WANG Y, Wang Y, Yu J, Meng X, et al
    The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues.
    Cancer Lett. 2022 Oct 17:215947. doi: 10.1016/j.canlet.2022.215947.
    PubMed     Abstract available
    
    
    
49. MYACHEVA K, Walsh A, Riester M, Pelos G, et al
    CRISPRi screening identifies CASP8AP2 as an essential viability factor in lung cancer controlling tumor cell death via the AP-1 pathway.
    Cancer Lett. 2022 Oct 14:215958. doi: 10.1016/j.canlet.2022.215958.
    PubMed     Abstract available
    
    
    
50. PALAZZO A, Hernandez-Vargas H, Goehrig D, Medard JJ, et al
    Transformed cells after senescence give rise to more severe tumor phenotypes than transformed non-senescent cells.
    Cancer Lett. 2022;546:215850.
    PubMed     Abstract available
    
    
    
51. ZHANG T, Zhang G, Chen X, Chen Z, et al
    Low-dose carbon monoxide suppresses metastatic progression of disseminated cancer cells.
    Cancer Lett. 2022;546:215831.
    PubMed     Abstract available
    
    
    September 2022
52. ZHANG C, Zhou L, Li S, Zhao J, et al
    Obesity accelerates immune evasion of non-small cell lung carcinoma via TFEB-dependent upregulation of Siglec-15 and glycolytic reprogramming.
    Cancer Lett. 2022 Sep 20:215918. doi: 10.1016/j.canlet.2022.215918.
    PubMed     Abstract available
    
    
    
53. CHEN TW, Hung WZ, Chiang SF, Chen WT, et al
    Dual inhibition of TGFbeta signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1.
    Cancer Lett. 2022;543:215795.
    PubMed     Abstract available
    
    
    
54. ZHANG P, Li B, Chen Q, Wang H, et al
    Glucose restriction induces ROS-AMPK-mediated CTR1 expression and increases cisplatin efficiency in NSCLC.
    Cancer Lett. 2022;543:215793.
    PubMed     Abstract available
    
    
    August 2022
55. HUANG H, Yang Y, Zhu Y, Chen H, et al
    Blood protein biomarkers in lung cancer.
    Cancer Lett. 2022 Aug 19:215886. doi: 10.1016/j.canlet.2022.215886.
    PubMed     Abstract available
    
    
    
56. BAHREYNI A, Liu H, Mohamud Y, Xue YC, et al
    A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice.
    Cancer Lett. 2022 Aug 19:215849. doi: 10.1016/j.canlet.2022.215849.
    PubMed     Abstract available
    
    
    
57. HU Y, Lu Y, Xing F, Hsu W, et al
    FGFR1/MAPK-directed brachyury activation drives PD-L1-mediated immune evasion to promote lung cancer progression.
    Cancer Lett. 2022 Aug 16:215867. doi: 10.1016/j.canlet.2022.215867.
    PubMed     Abstract available
    
    
    
58. ZHANG N, Gao Y, Huang Z, Dai P, et al
    PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy.
    Cancer Lett. 2022 Aug 1:215852. doi: 10.1016/j.canlet.2022.215852.
    PubMed     Abstract available
    
    
    July 2022
59. ZHAO W, Jin L, Chen P, Li D, et al
    Colorectal cancer immunotherapy-Recent progress and future directions.
    Cancer Lett. 2022 Jul 7:215816. doi: 10.1016/j.canlet.2022.215816.
    PubMed     Abstract available
    
    
    
60. SHANG C, Sun Y, Wang Y, Shi H, et al
    CXCL10 conditions alveolar macrophages within the premetastatic niche to promote metastasis.
    Cancer Lett. 2022;537:215667.
    PubMed     Abstract available
    
    
    June 2022
61. LI J, Zhang Q, Jiang D, Shao J, et al
    CircRNAs in lung cancer- role and clinical application.
    Cancer Lett. 2022 Jun 30:215810. doi: 10.1016/j.canlet.2022.215810.
    PubMed     Abstract available
    
    
    
62. YIN H, Wang X, Zhang X, Zeng Y, et al
    Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].
    Cancer Lett. 2022 Jun 16:215792. doi: 10.1016/j.canlet.2022.215792.
    PubMed    
    
    
    
63. CHEN B, Song Y, Zhan Y, Zhou S, et al
    Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway.
    Cancer Lett. 2022 Jun 11:215783. doi: 10.1016/j.canlet.2022.215783.
    PubMed     Abstract available
    
    
    
64. LI S, Qu Y, Liu L, Zhang X, et al
    Proteomic analysis of plasma-derived exosomes identifies biomarkers that distinguish brain and liver metastasis in lung cancer patients.
    Cancer Lett. 2022 Jun 9:215782. doi: 10.1016/j.canlet.2022.215782.
    PubMed     Abstract available
    
    
    
65. GAO J, Zhang LX, Ao YQ, Jin C, et al
    Elevated circASCC3 limits antitumor immunity by sponging miR-432-5p to upregulate C5a in non-small cell lung cancer.
    Cancer Lett. 2022;543:215774.
    PubMed     Abstract available
    
    
    May 2022
66. SUN Y, Sun H, Qi Y, Pan M, et al
    Ring finger protein 6 enhances chemo-resistance by transcriptionally activating proliferating cell nuclear antigen expression and attenuating DNA damage in lung adenocarcinoma.
    Cancer Lett. 2022;534:215609.
    PubMed     Abstract available
    
    
    
67. TIAN Y, Ma J, Jing X, Zhai X, et al
    Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy.
    Cancer Lett. 2022;541:215719.
    PubMed     Abstract available
    
    
    April 2022
68. LOU Y, Lu J, Zhang Y, Gu P, et al
    The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma.
    Cancer Lett. 2022;532:215599.
    PubMed     Abstract available
    
    
    
69. SHI Y, Xu Y, Xu Z, Wang H, et al
    TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression.
    Cancer Lett. 2022;532:215583.
    PubMed     Abstract available
    
    
    
70. TSENG PC, Chen CL, Lee KY, Feng PH, et al
    Epithelial-to-mesenchymal transition hinders interferon-gamma-dependent immunosurveillance in lung cancer cells.
    Cancer Lett. 2022 Apr 28:215712. doi: 10.1016/j.canlet.2022.215712.
    PubMed     Abstract available
    
    
    
71. TAROMI S, Firat E, Simonis A, Braun LM, et al
    Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
    Cancer Lett. 2022 Apr 26:215697. doi: 10.1016/j.canlet.2022.215697.
    PubMed     Abstract available
    
    
    
72. FU L, Deng R, Huang Y, Yang X, et al
    Corrigendum to "DGKA interacts with SRC/FAK to promote the metastasis of non-small cell lung cancer" [Canc. Lett. (2022 Apr 28) 532 215585].
    Cancer Lett. 2022 Apr 24:215696. doi: 10.1016/j.canlet.2022.215696.
    PubMed    
    
    
    
73. TAROMI S, Firat E, Simonis A, Braun LM, et al
    Retraction notice to "Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer" [Canc. Lett. 520 (2021) 385-399].
    Cancer Lett. 2022 Apr 20:215680. doi: 10.1016/j.canlet.2022.215680.
    PubMed     Abstract available
    
    
    
74. YAN R, Fan X, Xiao Z, Liu H, et al
    Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/beta-Catenin activity and cancer stemness.
    Cancer Lett. 2022;531:83-97.
    PubMed     Abstract available
    
    
    March 2022
75. WANG J, Wren JD, Ding Y, Chen J, et al
    EWI2 promotes endolysosome-mediated turnover of growth factor receptors and integrins to suppress lung cancer.
    Cancer Lett. 2022 Mar 23:215641. doi: 10.1016/j.canlet.2022.215641.
    PubMed     Abstract available
    
    
    February 2022
76. CHEN H, Zhao L, Meng Y, Qian X, et al
    Sulfonylurea receptor 1-expressing cancer cells induce cancer-associated fibroblasts to promote non-small cell lung cancer progression.
    Cancer Lett. 2022 Feb 28:215611. doi: 10.1016/j.canlet.2022.215611.
    PubMed     Abstract available
    
    
    
77. SCHREIBER C, Gruber A, Rosswag S, Saraswati S, et al
    Loss of ASAP1 in the MMTV-PyMT model of luminal breast cancer activates AKT, accelerates tumorigenesis, and promotes metastasis.
    Cancer Lett. 2022 Feb 15:215600. doi: 10.1016/j.canlet.2022.215600.
    PubMed     Abstract available
    
    
    
78. YANG X, Zeng Z, Jie X, Wang Y, et al
    Arginine methyltransferase PRMT5 methylates and destabilizes Mxi1 to confer radioresistance in non-small cell lung cancer.
    Cancer Lett. 2022;532:215594.
    PubMed     Abstract available
    
    
    
79. FU L, Deng R, Huang Y, Yang X, et al
    DGKA interacts with SRC/FAK to promote the metastasis of non-small cell lung cancer.
    Cancer Lett. 2022 Feb 4:215585. doi: 10.1016/j.canlet.2022.215585.
    PubMed     Abstract available
    
    
    
80. WEI K, Ma Z, Yang F, Zhao X, et al
    M2 macrophage-derived exosomes promote lung adenocarcinoma progression by delivering miR-942.
    Cancer Lett. 2022;526:205-216.
    PubMed     Abstract available
    
    
    
81. FISK JN, Mahal AR, Dornburg A, Gaffney SG, et al
    Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma.
    Cancer Lett. 2022;526:346-351.
    PubMed     Abstract available
    
    
    
82. ZHANG K, Chen J, Li C, Yuan Y, et al
    Exosome-mediated transfer of SNHG7 enhances docetaxel resistance in lung adenocarcinoma.
    Cancer Lett. 2022;526:142-154.
    PubMed     Abstract available
    
    
    January 2022
83. CHENG Z, Lu C, Wang H, Wang N, et al
    Long noncoding RNA LHFPL3-AS2 suppresses metastasis of non-small cell lung cancer by interacting with SFPQ to regulate TXNIP expression.
    Cancer Lett. 2022;531:1-13.
    PubMed     Abstract available
    
    
    
84. LUO F, Lu FT, Cao JX, Ma WJ, et al
    HIF-1alpha inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer.
    Cancer Lett. 2022 Jan 25. pii: S0304-3835(22)00043.
    PubMed     Abstract available
    
    
    
85. GOU W, Yu X, Wu S, Wu H, et al
    Targeted inhibition of acidic nucleoplasmic DNA-binding protein 1 enhances radiosensitivity of non-small cell lung cancer.
    Cancer Lett. 2022 Jan 19. pii: S0304-3835(22)00036.
    PubMed     Abstract available
    
    
    
86. CHEN F, Liu J, Song X, DuCote TJ, et al
    EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.
    Cancer Lett. 2022;524:151-160.
    PubMed     Abstract available
    
    
    December 2021
87. CHAKRABORTY S, Utter MB, Frias MA, Foster DA, et al
    Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin.
    Cancer Lett. 2021;522:164-170.
    PubMed     Abstract available
    
    
    November 2021
88. LIU S, Zhan N, Gao C, Xu P, et al
    Long noncoding RNA CBR3-AS1 mediates tumorigenesis and radiosensitivity of non-small cell lung cancer through redox and DNA repair by CBR3-AS1 /miR-409-3p/SOD1 axis.
    Cancer Lett. 2021;526:1-11.
    PubMed     Abstract available
    
    
    
89. WANG T, Liu Z, She Y, Deng J, et al
    A novel protein encoded by circASK1 ameliorates gefitinib resistance in lung adenocarcinoma by competitively activating ASK1-dependent apoptosis.
    Cancer Lett. 2021;520:321-331.
    PubMed     Abstract available
    
    
    
90. MEEUSEN B, Cortesi EE, Domenech Omella J, Sablina A, et al
    PPP2R4 dysfunction promotes KRAS-mutant lung adenocarcinoma development and mediates opposite responses to MEK and mTOR inhibition.
    Cancer Lett. 2021;520:57-67.
    PubMed     Abstract available
    
    
    October 2021
91. GONG L, Shu J, Chen X, Pan H, et al
    DEPTOR inhibits lung tumorigenesis by inactivating the EGFR-mTOR signals.
    Cancer Lett. 2021;519:263-276.
    PubMed     Abstract available
    
    
    
92. ZHAO W, Yu D, Chen Z, Yao W, et al
    Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
    Cancer Lett. 2021;519:141-149.
    PubMed     Abstract available
    
    
    
93. LIANG R
    Letter to the editor regarding "XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a".
    Cancer Lett. 2021;524:193.
    PubMed    
    
    
    
94. LIU C, Xiang X, Han S, Lim HY, et al
    Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer.
    Cancer Lett. 2021;524:91-102.
    PubMed     Abstract available
    
    
    
95. ZHANG J, Wu Q, Zhu L, Xie S, et al
    SERPINE2/PN-1 regulates the DNA damage response and radioresistance by activating ATM in lung cancer.
    Cancer Lett. 2021 Oct 11. pii: S0304-3835(21)00511.
    PubMed     Abstract available
    
    
    
96. DA COSTA V, van Vliet SJ, Carasi P, Frigerio S, et al
    The Tn antigen promotes lung tumor growth by fostering immunosuppression and angiogenesis via interaction with Macrophage Galactose-type lectin 2 (MGL2).
    Cancer Lett. 2021;518:72-81.
    PubMed     Abstract available
    
    
    
97. TINGLEI H, Biying C, Feng W, Weiyang C, et al
    Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer.
    Cancer Lett. 2021 Oct 7. pii: S0304-3835(21)00518.
    PubMed     Abstract available
    
    
    September 2021
98. YANG F, Duan M, Zheng F, Yu L, et al
    Fas signaling in adipocytes promotes low-grade inflammation and lung metastasis of colorectal cancer through interaction with Bmx.
    Cancer Lett. 2021;522:93-104.
    PubMed     Abstract available
    
    
    
99. TANIMURA K, Yamada T, Horinaka M, Katayama Y, et al
    Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.
    Cancer Lett. 2021;522:119-128.
    PubMed     Abstract available
    
    
    
100. XU Y, Chen Y, Yao Y, Xie H, et al
     VIRMA contributes to non-small cell lung cancer progression via N(6)-methyladenosine-dependent DAPK3 post-transcriptional modification.
     Cancer Lett. 2021 Sep 11. pii: S0304-3835(21)00422.
     PubMed     Abstract available
     
     
     
101. WANG J, Dai Z, Miao Y, Zhao T, et al
     Carbon ion ((12)C(6+)) irradiation induces the expression of Klrk1 in lung cancer and optimizes the tumor microenvironment based on the NKG2D/NKG2D-Ls pathway.
     Cancer Lett. 2021;521:178-195.
     PubMed     Abstract available
     
     
     August 2021
102. JIANG Y, Zhan H, Zhang Y, Yang J, et al
     ZIP4 promotes non-small cell lung cancer metastasis by activating snail-N-cadherin signaling axis.
     Cancer Lett. 2021 Aug 24. pii: S0304-3835(21)00420.
     PubMed     Abstract available
     
     
     
103. PARK MS, Yang AY, Lee JE, Kim SK, et al
     GALNT3 suppresses lung cancer by inhibiting myeloid-derived suppressor cell infiltration and angiogenesis in a TNFR and c-MET pathway-dependent manner.
     Cancer Lett. 2021 Aug 17. pii: S0304-3835(21)00404.
     PubMed     Abstract available
     
     
     
104. TAROMI S, Firat E, Simonis A, Braun LM, et al
     Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.
     Cancer Lett. 2021 Aug 15. pii: S0304-3835(21)00401.
     PubMed     Abstract available
     
     
     July 2021
105. LIN S, Li Y, Wang D, Huang C, et al
     Fascin promotes lung cancer growth and metastasis by enhancing glycolysis and PFKFB3 expression.
     Cancer Lett. 2021;518:230-242.
     PubMed     Abstract available
     
     
     
106. JIN M, Li G, Liu W, Wu X, et al
     Cigarette smoking induces aberrant N(6)-methyladenosine of DAPK2 to promote non-small cell lung cancer progression by activating NF-kappaB pathway.
     Cancer Lett. 2021;518:214-229.
     PubMed     Abstract available
     
     
     
107. HUANG J, Tian F, Song Y, Cao M, et al
     A feedback circuit comprising EHD1 and 14-3-3zeta sustains beta-catenin/c-Myc-mediated aerobic glycolysis and proliferation in non-small cell lung cancer.
     Cancer Lett. 2021;520:12-25.
     PubMed     Abstract available
     
     
     June 2021
108. HAN HJ, Sung JY, Kim SH, Yun UJ, et al
     Fibronectin regulates anoikis resistance via cell aggregate formation.
     Cancer Lett. 2021;508:59-72.
     PubMed     Abstract available
     
     
     
109. ZHANG J, Zeng Y, Xing Y, Li X, et al
     Myristoylation-mediated phase separation of EZH2 compartmentalizes STAT3 to promote lung cancer growth.
     Cancer Lett. 2021 Jun 5. pii: S0304-3835(21)00266.
     PubMed     Abstract available
     
     
     
110. GABASA M, Radisky ES, Ikemori R, Bertolini G, et al
     MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence.
     Cancer Lett. 2021;507:1-12.
     PubMed     Abstract available
     
     
     May 2021
111. JIANG ZB, Wang WJ, Xu C, Xie YJ, et al
     Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
     Cancer Lett. 2021;515:36-48.
     PubMed     Abstract available
     
     
     
112. ZHANG H, Jiang H, Zhu L, Li J, et al
     Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives.
     Cancer Lett. 2021 May 18. pii: S0304-3835(21)00224.
     PubMed     Abstract available
     
     
     April 2021
113. WANG J, Hu T, Wang Q, Chen R, et al
     Repression of the AURKA-CXCL5 axis induces autophagic cell death and promotes radiosensitivity in non-small-cell lung cancer.
     Cancer Lett. 2021;509:89-104.
     PubMed     Abstract available
     
     
     March 2021
114. MA Y, Wang L, He F, Yang J, et al
     LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
     Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
     PubMed     Abstract available
     
     
     
115. TRAVER G, Sekhar KR, Crooks PA, Keeney DS, et al
     Targeting NPM1 in irradiated cells inhibits NPM1 binding to RAD51, RAD51 foci formation and radiosensitizes NSCLC.
     Cancer Lett. 2021;500:220-227.
     PubMed     Abstract available
     
     
     February 2021
116. DANG N, Lin Y, Waer M, Sprangers B, et al
     Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
     Cancer Lett. 2021;503:151-162.
     PubMed     Abstract available
     
     
     January 2021
117. LI Y, Chen Y, Miao L, Wang Y, et al
     Stress-induced upregulation of TNFSF4 in cancer-associated fibroblast facilitates chemoresistance of lung adenocarcinoma through inhibiting apoptosis of tumor cells.
     Cancer Lett. 2021;497:212-220.
     PubMed     Abstract available
     
     
     
118. LI X, Chen M, Lu W, Tang J, et al
     Targeting FAPalpha-expressing tumor-associated mesenchymal stromal cells inhibits triple-negative breast cancer pulmonary metastasis.
     Cancer Lett. 2021 Jan 19. pii: S0304-3835(21)00029.
     PubMed     Abstract available
     
     
     
119. GRILLO E, Corsini M, Ravelli C, di Somma M, et al
     A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis.
     Cancer Lett. 2021;496:84-92.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.